MedTrace Logo

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

NCT02085265 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-05-06

No results posted yet for this study

Summary

To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting enzyme inhibitor (ACEI).

Conditions

Interventions

DRUG

Perindopril

Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)

DRUG

Telmisartan

Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)

Sponsors & Collaborators

  • Alzheimer's Drug Discovery Foundation

    collaborator OTHER

  • Weston Brain Institute

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Sandra Black, MD · Sunnybrook Health Sciences Centre

  • Krista Lanctot, PhD · Sunnybrook Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02085265 on ClinicalTrials.gov